Bioprojet

Privately held: no public share price

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
Histamine H3 receptor (antagonist / inverse agonist)Small molecule
Myotonic Dystrophy Type 1NarcolepsyIdiopathic HypersomniaPrader-Willi Syndrome

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Pitolisant (Wakix)Phase 3Prader-Willi Syndrome
Est. primary completion 2027-04 · NCT06366464 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Pitolisant (Wakix)Phase 3Prader-Willi Syndrome
Est. primary completion 2030-08 · NCT07219485 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

September 2026ApprovalPitolisant (Wakix)Wakix approved in Japan for narcolepsy and OSAS-associated sleepiness
JP, MHLW · Viatris · Source ↗

Financial reports

No financial reports recorded.